In patients with severe thrombocytopenia (possibly less than 50 × 109/L, and particularly less than 20 × 109/L) undergoing high-risk procedures, where local hemostatic measures cannot be used, the European Association for the Study of the Liver suggests that platelet transfusion or use of thrombopoietin receptor agonists may be considered on a case-by-case basis.8 In our study, experts agreed that a platelet count of 50 × 109/L was the most appropriate transfusion target in patients having high-risk procedures. The gene discussed is MPL; the disease is Thrombocytopenia.